ArticleClinical kidney journal2019
An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.
Article in Clinical kidney journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Beyond complement: comprehensive assessment of factor XIII plasma dynamics and genetics in atypical hemolytic uremic syndrome.Research and practice in thrombosis and haemostasis · 2026Article
- Successful term pregnancy after renal transplant in end-stage renal disease with complement factor H-related mutation: A case report.World journal of transplantation · 2026Article
- Cytomegalovirus viremia associated with systemic thrombotic microangiopathy after kidney transplantation: a case report.Frontiers in medicine · 2026Article
- The von Willebrand factor/ADAMTS13 ratio as an indicator of venous thromboembolism risk: results from the RETROVE project.Journal of thrombosis and thrombolysis · 2026Article
- Establishing a rapid-response multidisciplinary service for thrombotic microangiopathies using a model of improvement framework: perspectives from a Brazilian quaternary hospital.Frontiers in medicine · 2026Article
- Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Spectrum and outcomes of thrombotic microangiopathies in nephrology: a 17-year cohort from a North African center.BMC nephrology · 2025Observational
- Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy.iMetaOmics · 2025Article
- The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.International journal of molecular sciences · 2024Review
- Article
- Thrombotic microangiopathy after kidney transplantation: Expanding etiologic and pathogenetic spectra.World journal of transplantation · 2024Review
- The Role of the Complement System in the Pathogenesis of Infectious Forms of Hemolytic Uremic Syndrome.Biomolecules · 2023Review
- Lethal immunotoxicity in high-dose systemic AAV therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Thrombotic microangiopathy after traumatic brain injury: A case report and review of the literature.Clinical case reports · 2023Article
- Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal Outcomes.Kidney medicine · 2023Article
- Article
- A Life-Threating Postpartum Atypical Hemolytic-Uremic Syndrome with Multiorgan Involvement.Journal of clinical medicine · 2022Article
- Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.International journal of molecular sciences · 2022Review
- Characteristics and genetic analysis of patients suspected with early-onset systemic lupus erythematosus.Pediatric rheumatology online journal · 2022Article
- First case of atypical haemolytic uraemic syndrome following COVID-19 vaccination with BNT162b2.Clinical kidney journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conditions presenting with signs of thrombotic microangiopathies (TMAs) comprise a wide spectrum of different diseases. While pathological hallmarks are thrombosis of arterioles and capillaries, clinical signs are mechanical haemolysis, thrombocytopenia and acute renal injury or neurological manifestations. The current classification of various syndromes of TMA is heterogeneous and often does not take the underlying pathophysiology into consideration. Therefore we propose a simplified classification based on the aetiology of different syndromes leading to TMA. We propose to categorize different TMA syndromes in hereditary and acquired forms and classify them based on the genetic background or underlying conditions. Of course, this classification is not always distinctly applicable in each case and from time to time reassessment of the established diagnosis is strongly recommended. The recommended treatment of TMA in the past was plasma exchange (PE). However, recently, the terminal complement inhibitor eculizumab became commercially available and has shown promising results in different open-label studies and case series. In our centre, first-line therapy is PE; however, patients are instantly switched to complement inhibitory therapy in case of treatment failure or intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.